Flora Luo assists the firm in biotechnology patent prosecution. She has extensive knowledge in the areas of genomic screening and cellular and molecular biology.
Prior to joining Wolf Greenfield, Flora was a graduate researcher in the Laboratory of Dr. Levi Garraway at the Dana Farber Cancer Institute in Boston, MA, where she mapped the landscape of resistance to cell cycle inhibitors in ER+ breast cancer with genomic screens and identified therapeutic strategies to combat resistance to CDK4/6 inhibition. As an undergraduate, she conducted her honors thesis in the Laboratory of Dr. Marianne Wessling-Resnick at the Harvard School of Public Health, where she used chemical genetics to characterize the role of the human hemochromatosis factor in cellular iron homeostasis.
- American Association for Cancer Research
- Harvard Mini MBA 2015
- Ruth L. Kirschstein National Research Service F31 Award (2015-2017)
- Tufts New England Case Competition 2015 – Third Place
- Le, X., Anthony, R., Razavi, P., Treacy, D.J., Luo, F. et al. (2016). Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. Cancer Discov 6, 1134-1147.
- Whittaker, S.R., Cowley, G.S., Wagner, S., Luo, F. et al. (2015). Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. Mol Cancer Ther 14, 2700-2711.
- Byrne, S.L., Buckett, P.D., Kim, J., Luo, F. et al. (2013). Ferristatin II promotes degradation of transferrin receptor-1 in vitro and in vivo. PLoS One 8, e70199.